Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | PEMBROSARC: pembrolizumab combinations for advanced sarcoma

Maud Toulmonde • 1 Jun 2018
ASCO 2018
Sarcoma Cyclophosphamide Epacadostat Pembrolizumab Tazemetostat
PEMBROSARC

Checkpoint inhibitors are an exciting therapy across a range of cancer types. Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Maud Toulmonde, MD, of the Institut Bergonié, Bordeaux, France, discusses the PEMBROSARC trial (NCT02406781), which investigated the use of pembrolizumab plus metronomic cyclophosphamide in advanced sarcoma.

More from Maud Toulmonde

1:51
Pazopanib for progressive desmoid tumors
Maud Toulmonde • 1 Jun 2018

Related Videos

0:51
Enhanced NK-cells in stage 4 sarcoma treatment
Vaishali Kumar • 8 Apr 2024
1:12
Predictive biomarkers for checkpoint inhibitors in sarcomas
Nadia Omelchenko • 8 Apr 2024
1:26
SAINT and LINNOVATE: combining ICIs and chemotherapy in advanced STC
Nadia Omelchenko • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals